Kristen Pumphrey is Senior Director of Conferences for PCMA. As the Association’s conference planner, she manages all aspects of site selection and coordination, vendor management, speaker recruitment, registration and onsite management. Previously, as Meetings Coordinator with the American Academy of
Pharmacy Direct and Indirect Remuneration (DIR) Value-based Pharmacy Reimbursement Reduces Drug Costs for Medicare Beneficiaries, Lowers Spending. Pharmacy direct and indirect remuneration, or Pharmacy DIR, is a form of value-based contracting in Medicare Part D. Pharmacy DIR increases the quality
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
Pennsylvania State Facts & Resources PBM Savings and Patient Impact in Pennsylvania Pharmacy benefit experts secure lower prescription drug costs and enable better health outcomes for patients. PBMs will save Pennsylvanians $45B across all Pennsylvania insurance markets over ten years
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase fees and/or add surcharges to transactions with pharmacies. This is based upon two arguments: 1) that independent pharmacies are becoming
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
Senior Advisor, MedImpact Mr. Marsella is currently a Senior Advisor at MedImpact. He has more than 20 years of experience in healthcare and pharmacy benefit administration and management. He was promoted to Senior Vice President, Sales and Marketing at the
©2024 PCMA. All Rights Reserved.
